“Chimpanzee Adenovirus Vector Ebola Vaccine.”. N Engl J Med 376 (10). N Engl J Med: 928-938. doi:10.1056/NEJMoa1410863.
. 2017. “Dna Priming And Influenza Vaccine Immunogenicity: Two Phase 1 Open Label Randomised Clinical Trials.”. Lancet Infect Dis 11 (12). Lancet Infect Dis: 916-24. doi:10.1016/S1473-3099(11)70240-7.
. 2011. “Prime-Boost Interval Matters: A Randomized Phase 1 Study To Identify The Minimum Interval Necessary To Observe The H5 Dna Influenza Vaccine Priming Effect.”. J Infect Dis 208 (3). J Infect Dis: 418-22. doi:10.1093/infdis/jit180.
. 2013. “Protection Against Malaria By Intravenous Immunization With A Nonreplicating Sporozoite Vaccine.”. Science 341 (6152). Science: 1359-65. doi:10.1126/science.1241800.
. 2013. “Safety And Immunogenicity Of Dna Vaccines Encoding Ebolavirus And Marburgvirus Wild-Type Glycoproteins In A Phase I Clinical Trial.”. J Infect Dis 211 (4). J Infect Dis: 549-57. doi:10.1093/infdis/jiu511.
. 2015.